Consistent for a role of CTGF in IPF, a recent open-label uncontrolled study suggested that a monoclonal antibody targeting CTGF, FG-3019, may be beneficial in a subset of IPF patients in terms of lung function decline and imaging-assessed fibrotic changes [23]. Here, CCN2 is linked to idiopathic pulmonary fibrosis.